Calypso Medical Technologies, the Seattle-based maker of a system to pinpoint radiation therapy for prostate cancer, said today that Ed Vertatschitsch has been named the company’s CEO. Vertatschitsch, who joined Calypso in 2003, has been at the helm on an interim basis since August, when former CEO Eric Meier left the company at a time of downsizing and reorganization of the company’s sales force. Vertatschitsch was previously the executive vice president of operations and R&D at Calypso before taking on the top job.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
